Troy Stiles, DO
Psychiatry · Billings, MTNPI 1437122207
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $192,497 of the $220,522 with a category attached, or 87.3%. Teva Pharmaceuticals USA, Inc. accounts for 72.0% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $75,536, 2.5 times the $29,721 reported in 2019. Among psychiatry clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 421 payments — averaging $523.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$159K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$25K
- Takeda Pharmaceuticals U.S.A., Inc.$23K
- Otsuka America Pharmaceutical, Inc.$13K
- AbbVie$368
- Supernus Pharmaceuticals, Inc.$297
- plus $937 from 11 others
What the payments were for
- Consulting fees$4,5302%
- Speaking & faculty fees$192,49787%
- Travel & lodging$17,2608%
- Food & beverage$5,8683%
- Education$3660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 219 | $158,845 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $24,998 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $22,508 |
| Otsuka America Pharmaceutical, Inc. | 50 | $12,569 |
| AbbVie(2 entities) | 19 | $368 |
| Supernus Pharmaceuticals, Inc. | 15 | $297 |
| Neurocrine Biosciences, Inc. | 8 | $168 |
| Johnson & Johnson | 9 | $164 |
| Ironshore Pharmaceuticals Inc. | 6 | $118 |
| Vanda Pharmaceuticals Inc. | 5 | $104 |
| Alkermes, Inc. | 6 | $103 |
| Sunovion Pharmaceuticals Inc. | 7 | $69 |
| Lundbeck LLC | 4 | $65 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Collegium Pharmaceutical, Inc. | 2 | $45 |
| Merck | 1 | $29 |
| Corium, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$75,057
- UZEDY$42,161
- AUSTEDO$39,406
- CAPLYTA$24,419
- TRINTELLIX$22,133
- REXULTI$11,762
How this compares
$220,522 in reported general payments places this provider in the 95th percentile of 82 psychiatry providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 38 | $241,456 |
| Invega TrinzaPaliperidone Palmitate | 20 | $184,855 |
| Austedo XrDeutetrabenazine | 13 | $165,541 |
| UzedyRisperidone | 40 | $145,206 |
| CaplytaLumateperone Tosylate | 78 | $140,142 |
| IngrezzaValbenazine Tosylate | 17 | $138,967 |
| RexultiBrexpiprazole | 31 | $92,528 |
| VraylarCariprazine Hcl | 52 | $84,798 |
| Aripiprazole | 157 | $25,200 |
| Lisdexamfetamine Dimesylate | 143 | $24,978 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 190 | $21,534 |
| Asenapine Maleate | 51 | $19,993 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $18,725 |
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $17,862 |
| VyvanseLisdexamfetamine Dimesylate | 49 | $17,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr, Uzedy | $158,845 | $552,20491 claims |
| Johnson & JohnsonInvega Trinza | $164 | $184,85520 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $24,998 | $140,14278 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $168 | $138,96717 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $12,569 | $92,52831 claims |
| AbbVieVraylar | $368 | $84,79852 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $22,508 | $31,93063 claims |
| Alkermes, Inc.Lybalvi | $103 | $18,72512 claims |
| MerckBelsomra | $29 | $10,70924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 82 psychiatry providers in Montana.
Other psychiatry in Billings
- Erin AmatoBillings$88K
- Reza Hosseini GhomiBillings$6K
- Justin KunzBillings$4K
- Svetlana YakovBillings$2K
- Faraz MasoodBillings$1K
- Eric ArzubiBillings$353
- Deborah MaltersBillings$284
- Katherine WeaverBillings$168
- Mariela Herrera RojasBillings$98
- Todd WojtanowiczBillings$86
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.